Anthera Pharmaceuticals (NASDAQ:ANTH) posted its earnings results on Monday, March 5th. The biopharmaceutical company reported ($0.73) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.82) by $0.09, Bloomberg Earnings reports.
Shares of Anthera Pharmaceuticals stock opened at $0.38 on Thursday. The stock has a market cap of $8.42, a price-to-earnings ratio of -0.11 and a beta of 2.22. Anthera Pharmaceuticals has a 12-month low of $0.31 and a 12-month high of $3.84.
A number of research firms recently issued reports on ANTH. Jefferies Group reiterated a “hold” rating and issued a $0.50 target price on shares of Anthera Pharmaceuticals in a research note on Thursday, March 15th. Piper Jaffray Companies lowered shares of Anthera Pharmaceuticals from an “overweight” rating to an “underweight” rating in a research note on Monday, March 12th. HC Wainwright restated a “buy” rating on shares of Anthera Pharmaceuticals in a research report on Tuesday, March 6th. Zacks Investment Research lowered shares of Anthera Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Wednesday, February 28th. Finally, Roth Capital assumed coverage on shares of Anthera Pharmaceuticals in a research report on Wednesday, February 21st. They issued a “buy” rating and a $10.00 price target on the stock. Two investment analysts have rated the stock with a sell rating, two have assigned a hold rating and two have issued a buy rating to the stock. Anthera Pharmaceuticals currently has a consensus rating of “Hold” and an average target price of $4.06.
Anthera Pharmaceuticals, Inc (Anthera) is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation, including enzyme replacement therapies and autoimmune diseases. The Company has two Phase III product candidates, liprotamase also known as Sollpura and blisibimod.
Receive News & Ratings for Anthera Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anthera Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.